CDMOs offering Cell-Line Development with mRNA
Cell-Line Development combined with mRNA is a common shortlist filter for sponsors evaluating CDMO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- 4basebio
4basebio manufactures high-quality synthetic DNA and RNA using proprietary cell-free amplification technology, supporting mRNA vaccines, viral vectors, gene editing, and cell/gene therapies from research through GMP-grade clinical production.
- AGC Biologics
Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- Aldevron
Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
- BioVectra
North American CDMO specializing in clinical-to-commercial biologics, small molecules, HPAPIs, and bioreagents with 50+ years of microbial fermentation and complex chemistry expertise across cGMP facilities in Canada.
- Biomay AG
GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities.
- Creative Biogene
Creative Biogene provides viral vector manufacturing, cell line development, and RNA therapeutic platforms including AAV, lentivirus, adenovirus production, circular RNA synthesis, and lipid nanoparticle formulation for gene therapy and vaccine applications.
- Curia
Global CDMO with 30+ years of experience offering integrated services across small molecule, generic APIs, sterile drug product, and biologics manufacturing, backed by 20+ facilities and 3,000+ professionals across North America, Europe, and India.
- ElevateBio
Advanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.
- Maravai LifeSciences
Leading provider of nucleic acid products, custom enzymes, and bioprocess analytics supporting vaccine, therapeutic, and diagnostic development from discovery through commercialization, with mRNA CDMO services including proprietary CleanCap® capping technology.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Porton Advanced
End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
- Samsung Biologics
Leading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
- Sophia CDMO
European CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Related: Cell-Line Development service page · mRNA modality page
Markdown mirror: /explore/svc_cell_line_development/mod_mrna.md